Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original research

The sex-related discrepancy in laboratory parameters of severe COVID-19 patients with diabetes: A retrospective cohort study

Maha O. Hammad a,*, Mahmoud M. Alseoudy b

a Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt
b Department of Anaesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Mansoura, Egypt

1. Introduction

Since December 2019, novel coronavirus–infected pneumonia (COVID-19) has rapidly spread throughout China and around the world [1,2]. Increasing evidence suggests that comorbid conditions have a vital role in the course and progression of COVID-19 [3]. Diabetes mellitus (DM) is identified as an independent risk factor for developing respiratory tract infections [4]. It was found that confirmed COVID-19 patients with diabetes are at higher risk of mortality than their non-diabetic counterparts [5,6].

Many studies have proven that there are considerable sex-specific differences in the laboratory parameters, as well as in the progression of COVID-19 patients as a whole [7,8], but these sex-associated differences were not efficiently investigated among severe COVID-19 patients with diabetes in particular, even though the role of sex differences in the risk and complications of diabetes is of fundamental importance [9,10].

This knowledge is essential to promote the development of relevant sex-based therapeutic methods and preventive strategies for severe COVID-19 patients with diabetes in an attempt to reduce the risk of fatality in this patient population and to allow for more awareness in terms of sex-specific risk factors.

Thus, this research aimed at exploring the possible roles of sex-specific differences in laboratory characteristics and the clinical outcome of diabetic patients with severe COVID-19 pneumonia. This study also focused on the potential feasibility of sex-related discrepancies in inflammatory ratios obtained from combinations of six inflammatory markers. The secondary endpoint will be to find other predictors of fatality among the study population.

Abstract

Aim: This study aimed at providing evidence to consider sex differences in interpretations of laboratory parameters of severe COVID-19 patients with diabetes.

Methods: For 118 diabetic patients, laboratory measurements and clinical outcomes were compared between males and females. This study also compared inflammatory ratios obtained from combinations of six inflammatory markers between the two groups. The risk factors for mortality were identified through logistic regression.

Results: Males were 54 (45.8%) and females were 64 (54.2%). Males showed a significant increase in ALT (P < 0.003), CRP (P = 0.03), mean platelet volume (MPV)-to-lymphocyte ratio (P = 0.001), and C-reactive protein-to-albumin ratio (P = 0.044), whereas females had a significant increase in lymphocytes (P < 0.005) and MPV (P < 0.01). In all participants, multivariate analysis illustrated that older age, male sex, increased serum total bilirubin, and decreased PO2 were significant independent predictors of mortality (P < 0.05).

Conclusion: In severe COVID-19 patients with diabetes, there were significant sex differences in many laboratory characteristics with a higher risk of mortality among males.

© 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
2. Methods

2.1. Study design

This is a retrospective, cohort observational analysis performed on severe COVID-19 patients with diabetes who were admitted to Mansoura University Hospital between July and November 2020. This study was approved by the Institutional Research Board (IRB) of the Faculty of Medicine, Mansoura University (approval number: R.20.12.1133). Informed consent was waived as the study involved no potential risk and no breach of privacy to patients. This manuscript adheres to the applicable STROBE guidelines.

2.2. Patients

This study included 118 patients previously diagnosed with diabetes (type 2) with hypoglycaemic agent prescriptions and random blood glucose >11.1 mmol/L. All patients of the study had a confirmed positive result for real-time polymerase chain reaction assay for COVID-19 nucleic acid from pharyngeal swab samples. All patients had been diagnosed with severe COVID-19 previously by a respiratory physician according to these criteria: arterial oxygen saturation (SaO₂) ≥92%, PaO₂ (arterial oxygen partial pressure)/FiO₂ (fraction of inspired oxygen) <300, respiratory rate >30 breaths/min, or lung infiltrates detected by CT were more than 50%. Patients were divided into two groups based on sex into male and female groups.

We excluded non-severe COVID-19 patients with diabetes, patients who had no history of diabetes, newly diagnosed patients with diabetes at isolation hospital, patients aged <18 years, pregnant females with COVID-19 infection and diabetes, severe COVID-19 patients with type 1 diabetes, and severe COVID-19 patients with missing data.

2.3. Data collection

Information on age, sex, and comorbidities was recorded upon hospital admission. The clinical outcome (either dead or improved) was obtained at the final date of follow-up (the end of November 2020). The following initial routine laboratory findings were assessed upon hospital admission: complete blood count (CBC), arterial blood gases (ABG), coagulation profile (d-dimer, INR, prothrombin time), liver function tests (serum albumin, alanine transaminase (ALT), aspartate transaminase (AST)), total bilirubin, serum creatinine, lactate dehydrogenase (LDH), and C-reactive protein (CRP).

Six inflammation-related ratios were obtained by dividing the four upregulated inflammatory markers [mean platelet volume (MPV), platelets, LDH, and CRP] by two downregulated inflammatory markers (lymphocytes and albumin). The six combinations of inflammatory markers examined were: MPV/MP, platelet/platelet count (10⁹/L) ratio; PLR=platelet count (10⁹/L)/lymphocyte count (10⁹/L) ratio; CLR=CRP (mg/L)/lymphocyte count (10⁹/L) ratio; CAR=CRP (mg/L)/serum albumin level (g/L) ratio; LAR=LDH (U/L)/serum albumin level (g/L) ratio; PAR=platelet count (10⁹/L)/serum albumin level (g/L) ratio.

2.4. Statistical analysis

Data were entered and analyzed using SPSS software (version 25.0). Differences between the two groups were analyzed using the chi-square test for categorical variables. Continuous variables were initially tested for normality using Kolmogorov-Smirnov test with data being normally distributed if P-value >0.05. Normally distributed continuous variables were compared via independent samples t-test, whereas the nonparametric Mann-Whitney U-test was used if the data were non-normally distributed. Univariate logistic regression was used to predict the likelihood of mortality using only one predictor. The multivariate logistic regression model was then applied to variables significant at the univariate analysis to create a prediction model for detecting significant “independent” predictors with their OR (95% CI). For any used tests, results were considered statistically significant if P-value <0.050.

3. Results

3.1. Patients’ clinic-demographic characteristics

The patients’ clinic-demographic data are demonstrated in Table 1. Of the entire patient cohort, the mean age was 63 (±9.7) years with 45 patients (38.2%) died at the final follow-up of this study. Besides, diabetes coexisted together with hypertension in 80 patients (67.8%). There were 64 females (54.2%) and 54 males (45.8%). Male patients with diabetes had a significantly higher mortality rate than female patients with diabetes (48.1% vs. 29.7%, P=0.04).

3.2. Comparison of laboratory characteristics between sexes

All patients with diabetes had abnormalities of d-dimer, LDH, and CRP at admission. Male patients with diabetes had a significant increase in RBC parameters, including RBC count, haematocrit, and haemoglobin than female patients with diabetes (P<0.05). Moreover, there was a significant decrease in lymphocyte count (P<0.005) and MPV (P=0.01) in male patients compared to females. There were other sex differences reported in which males had a significant increase in ALT (P<0.003) and CRP (P=0.03) than females. Meanwhile, other laboratory parameters were not different in both sexes (P>0.05) (Table 2).

3.3. Sex-related differences in the inflammation-related ratios

The inflammatory ratios were similar in both male and female groups except for MPV/MP and CAR in which male patients with diabetes had higher MPV/MP (median of 8 vs. 6.3, P=0.001) and CAR (median of 1.4 vs. 2, P=0.044) than females (Table 3).

3.4. Predictors of mortality among severe COVID-19 patients with diabetes

Univariate logistic regression analysis revealed that older age (P<0.005), male sex (P=0.04), increased serum bilirubin levels (P=0.04), and increased ALT (P=0.01) were demonstrated to be significant positive predictors of mortality among severe COVID-19 patients with diabetes, whereas PO2 (P=0.001) and serum albumin levels (P=0.04) were demonstrated to be negative predictors of mortality (Table 4).

The multivariable logistic regression model was statistically significant, χ² (df) = 39.484(6), P<0.0005. The model correctly classified 81.9% of cases. Specificity was 86.04%, and PPV was 84.09%, whereas sensitivity was 75.5%, and NPV was 78.6%. Age, sex, PO2, and total bilirubin remained significantly associated with mortality among severe COVID-19 patients with diabetes. Older age, male sex, increased serum total bilirubin levels were significant positive independent predictors of mortality. The odds ratio of mortality increased 1.11-fold for older age, 4.788-fold for the male sex, and 6.359-fold for increased serum total bilirubin, whereas PO2 was a significant negative independent predictor of mortality; PO2 had 0.949 times lower odds to exhibit mortality (Table 5).
Table 1
Patients’ clinic-demographic data.

| Parameter                  | All patients (n = 118) | Male patients (n = 54) | Female patients (n = 64) | Statistic | P      |
|---------------------------|------------------------|------------------------|--------------------------|-----------|--------|
| Age (years)               | 63.1 ± 9.7             | 63.7 ± 9.9             | 62.8 ± 9.6               | t = 0.511  | 0.611  |
| Age categories ≤59 years  | 38 (32.2%)             | 18 (33.3%)             | 20 (31.3%)               | χ² (df) = 138 (2) | **0.933 |
| 60–70 years               | 52 (44%)               | 24 (44.4%)             | 28 (43.8%)               |           |        |
| ≥70 years                 | 28 (23.8%)             | 12 (22.2%)             | 16 (25%)                 |           |        |
| Outcome                   |                        |                        |                          |           |        |
| Dead                      | 45 (38.2%)             | 26 (48.1%)             | 19 (29.7%)               | χ² (df) = 4.231 (1) | **0.04 |
| Improved                  | 73 (61.8%)             | 28 (51.9%)             | 45 (70.3%)               |           |        |
| Comorbidity               |                        |                        |                          |           |        |
| DM only                    | 38 (32.2%)             | 22 (40.7%)             | 16 (25%)                 | χ² (df) = 3.324 (1) | **0.07 |
| DM with hypertension      | 80 (67.8%)             | 32 (59.3%)             | 48 (75%)                 |           |        |

P-value by ‘Independent samples t-test’ (data are presented as mean ± SD). P-value by ‘Chi-square test’ (data are presented as count and percentage. Z-test for column proportions (with adjusted P value by Bonferroni method) is presented by letters; similar letter = insignificant difference.

Table 2
Laboratory characteristics of male and female patients with diabetes and severe COVID-19.

| Parameter                  | Reference range | All patients (n = 118) | Male patients (n = 54) | Female patients (n = 64) | P      |
|---------------------------|-----------------|------------------------|------------------------|--------------------------|--------|
| Haematology               |                 |                        |                        |                          |        |
| RBC (m/L)                 | 4.59 (4.31–4.98) | 4.8 (4.3–5.2)          | 4.5 (4.3–4.8)          | 0.03                     |        |
| Haematocrit (%)           | 38.5 (35.1–41.3) | 40.2 (37.3–41.9)       | 36.5 (34.9–40.1)       | <0.005                   |        |
| Haemoglobin (g/dL)        | 12.7 (11.2–13.3) | 13.2 (11.9–14.6)       | 12 (10.9–12.9)         | 0.001                    |        |
| WBC (×10^9/L)             | 4.11            | 10.6 (6.6–12.2)        | 9.6 (6.6–14.1)         | 0.66                     |        |
| Lymphocyte count (×10^9/L)| 1.3 (1–1.8)     | 1.2 (0.9–1.5)          | 1.6 (1.1–2.3)          | <0.005                   |        |
| Lymphocyte %              | 10.585          | 14.1 (10.5–20)         | 12 (10.2–16.7)         | 0.03                     |        |
| Platelet (×10^9/L)        | 140–450         | 195 (125–245)          | 215 (156–286)          | 0.3                      |        |
| Mean platelet volume (fL)| 7.2–11.8        | 8.9 (8.5–9.6)          | 9.2 (8.6–10.1)         | 0.01                     |        |
| Arterial blood gases      |                 |                        |                        |                          |        |
| PH                        | 7.35–7.45       | 7.39 (7.34–7.43)       | 7.39 (7.35–7.44)       | 0.634                    |        |
| PaCO₂, mmHg               | 38.3 (33–47.6)  | 40.5 (33–47.6)         | 38.8 (33–47.7)         | 0.5                      |        |
| PaO₂, mmHg                | 93 ± 108        | 56.6 (41–76.6)         | 62.4 (47.2–79.3)       | 0.32                     |        |
| SaO₂ (%)                  | 95 ± 100        | 87 (71–91.9)           | 89 (77–93)             | 0.4                      |        |
| Na⁺ (mmol/L)              | 136–145         | 139 (135–146)          | 139 (133–148)          | 0.27                     |        |
| K⁺ (mmol/L)               | 3.5–5.1         | 3.8 (3.5–4.3)          | 4.1 (3.5–4.3)          | 0.7                      |        |
| Biochemistry              |                 |                        |                        |                          |        |
| Albumin (g/L)             | 35–55           | 34 (31–37)             | 33 (31–35)             | 0.2                      |        |
| AST (U/L)                 | 5–40            | 37.5 (26–52)           | 38.5 (24–52)           | 0.52                     |        |
| ALT (U/L)                 | 7–56            | 31 (21–50)             | 38.5 (30–59)           | 0.003                    |        |
| Total bilirubin (mg/dl)   | 0.2–1.2         | 0.8 (0.6–0.9)          | 0.7 (0.6–0.8)          | 0.16                     |        |
| Creatinine (mg/dl)        | 1.2 (0.9–1.3)   | 1.1 (0.9–1.2)          | 1.2 (1–1.5)            | 0.75                     |        |
| Lactate dehydrogenase (U/L)| 240–480       | 647 (549–845)          | 654 (466–926)          | 0.860                    |        |
| C-reactive protein (mg/L) | <10             | 53.5 (23.5–96)         | 45.3 (12.73)           | 0.03                     |        |
| Coagulation profile       |                 |                        |                        |                          |        |
| Prothrombin time (s)      | 12–13 s         | 14.5 (13–15.2)         | 14.3 (13–15.9)         | 0.46                     |        |
| INR                        | 0.8–1.2         | 1.1 (1.1–1.2)          | 1.05 (1–1.3)           | 0.78                     |        |
| D-dimer (ng/mL)           | <250            | 420 (250–1350)         | 368 (215–1880)         | 0.55                     |        |

P-value by Mann–Whitney U test ([data are presented as median and interquartile range (IQR)]. Abbreviations: RBC: red blood cells; WBC: white blood cells; PaCO₂: arterial carbon dioxide partial pressure; PaO₂: arterial oxygen partial pressure; SaO₂: arterial oxygen saturation; AST: aspartate transaminase; ALT: alanine transaminase; INR: international normalized ratio.

Table 3
Comparison between male and female patients with severe COVID-19 pneumonia and diabetes regarding the inflammatory ratios.

| Ratio                     | All patients (n = 118) | Male patients (n = 54) | Female patients (n = 64) | P      |
|---------------------------|------------------------|------------------------|--------------------------|--------|
| MPVLR                     | 7 (5.1–8.6)            | 8 (6.5–10.3)           | 6.3 (4.3–7.5)            | 0.001  |
| PLR                       | 156 (97.5–224)         | 164 (120–224)          | 150.5 (83.3–230)         | 0.12   |
| CLR                       | 38.8 (17.3–68.3)       | 28.2 (13.6–68.6)       | 39.9 (18.7–73.6)         | 0.421  |
| CAR                       | 1.7 (0.66–2.6)         | 2 (1.01–2.8)           | 1.4 (0.39–2)             | 0.044  |
| LAR                       | 19.4 (12.8–24.9)       | 19.4 (16.1–24.7)       | 19.3 (12.5–27.8)         | 0.78   |
| PAR                       | 5.9 (4.4–8.4)          | 5.9 (4.5–7.1)          | 5.9 (4.4–9.1)            | 0.3    |

P-value by Mann–Whitney U test ([data are presented as median and interquartile range (IQR)]. Abbreviations: MPVLR: mean platelet volume/lymphocyte ratio; PLR: platelet/lymphocyte ratio; CLR: CRP/lymphocyte ratio; CAR: CRP/albumin ratio; LAR: LDH/albumin ratio; PAR: platelet/albumin ratio.

4. Discussion
There is increasing evidence that sex disparity is important in epidemiology, pathophysiology, treatment, and outcomes in many diseases. Males and females exhibit a different response to viral infections in which females mount a stronger immune response because estrogen and progesterone can help increase the innate and adaptive immune responses, and many immune genes are
Table 4
Univariate logistic regression analysis for predicting the likelihood of mortality among severe COVID-19 patients with diabetes.

| Parameter | Crude OR | CI        | P     |
|-----------|----------|-----------|-------|
| Age       | 1.099    | 1.047–1.153 | <0.005 |
| Sex       | 2.199    | 1.032–4.687 | 0.04  |
| PO2       | 0.965    | 0.944–0.986 | 0.001 |
| Albumin   | 0.413    | 0.177–0.962 | 0.04  |
| Bilirubin | 11.348   | 1.766–72.431 | 0.01  |
| ALT       | 1.025    | 1.005–1.045 | 0.01  |

P-value by univariate logistic regression analysis. Abbreviations: Crude OR, crude odds ratio; 95% CI, 95% confidence interval.

The odds of mortality among severe COVID-19 patients with diabetes was 1.99 for each year increase in age. Sex and PO2 were found to be significant predictors of mortality among COVID-19 patients. However, the PO2 level in females of this study is still within normal range, and has not risen to affect the prognosis of the disease.

The results could be explained by multiple hypotheses, such as direct viral cytopotoxicity through angiotensin-converting enzyme-2, hepatoatopic medications, immune-mediated injury, and passive congestion [23].

This study demonstrated a higher CRP level for all 118 patients with diabetes (median of 53.5 mg/L). Elevation CRP level was associated with an increased risk of cardiovascular sequel and mortality in patients with type-2 diabetes [24]. Moreover, Liu et al. demonstrated that COVID-19 patients with CRP > 41.8 mg/L were more likely to develop severe disease and worse outcomes [25]. Further, our data illustrated that males had a higher CRP level than females (median of 65 vs. 45.3 mg/L, P = 0.03). This finding was in agreement with the finding of another study [13], suggesting an enhanced inflammatory process and poor prognosis in males.

Inflammation-related ratios were of great clinical significance and became a research hotspot as they may serve as simple, convenient, and cost-effective biomarkers to monitor the disease course. To date, a number of inflammation-related ratios such as the PLR [26] and CAR [27] have been proposed as prognostic markers in COVID-19 pneumonia. To our knowledge, no study has investigated the sex differences in inflammation-related ratios in severe COVID-19 pneumonia. In that context, our current study investigated sex discrepancies in inflammatory ratios in severe COVID-19 patients with diabetes.

The MPVLR was considered a simple biomarker of inflammation and was initially proposed by Hudzik et al. [28] in 2016. Our results illustrated that males tend to have more MPVLR than females (P = 0.001), indicating a higher risk of inflammation and thrombosis in males. MPVLR, which was calculated using MPV instead of the platelet count, was claimed to be more representative of platelet activity than PLR [29]. Many studies have suggested that MPVLR may be a predictor of worse outcomes linking inflammation and thrombosis in diabetic patients with myocardial infarction [30] and diabetic nephropathy [31].

CRP is a positive acute-phase reactant significantly increasing during infection and inflammation, and it is upregulated by pro-inflammatory cytokines, especially IL-6 [32]. Albumin, on the other hand, is a negative acute-phase reactant decreasing during infection and/or inflammation. The CAR, first introduced by Fairclough et al., is believed to The CAR, first introduced by Fairclough et al. [33], is believed to be an inflammation-based prognostic score. Previous studies had suggested that a combination of albumin and CRP into a single ratio might have clinical implications in many inflammatory diseases than CRP or albumin alone [34,35]. Moreover, CAR had the potential to detect high-risk patients for a high...
intracoronary thrombus burden [36]. It is now well appreciated that the innate immune response and elevated acute phase reactants, such as CRP may contribute to COVID-associated hypercoagulability [37]. Compared to females, males had higher CAR (P = 0.044), reflecting that males tend to experience higher inflammatory burden, which increases the possibility of sex effect in the association between inflammation and COVID-19, especially among diabetics. As studies had reported the fundamental role of sex-differences in complication, as well as manifestation, and management of diabetes [10,38]. The coexistence of diabetes with severe COVID-19 pneumonia has been reported to increase disease severity and mortality risk [39,40]. Therefore, early risk prediction of death among this vulnerable population has become a serious health challenge.

In our cohort, older age was an important independent predictor of mortality. Many studies had confirmed that increased age was associated with death in patients with COVID-19 as a whole [41] or among diabetics [6,42].

Moreover, our data illustrated that diabetic males with severe COVID-19 were associated with an increased risk of death with 4.788 times higher odds for mortality. This finding was in parallel to those of Agarwal et al. [43]: they included 1126 hospitalized patients with diabetes and COVID-19 and found that in all age categories, mortality was higher with increasing body mass index in males compared with females. However, this result was in disagreement with another study by Acharya et al. [6], on a Korean cohort of 55 COVID-19 patients with diabetes as they found male sex could not predict mortality. This discrepancy may be due to two factors: First: ethnic differences. Second, the study was performed on a relatively small number of 55 COVID-19 patients with diabetes.

Additionally, we also found that increased serum total bilirubin level was a high-risk factor for mortality in severe COVID-19 patients with diabetes with 6.359 times higher odds for mortality. This finding was in accordance with other studies [44,45]. Further, low PO2 was an effective predictor of mortality in our study. This result was in harmony with a study done by Xie et al. [46], which revealed that hypoxaemia was an independent predictor of mortality in COVID-19 patients.

In view of that study, the presence of advanced age, male sex, increased serum total bilirubin, and decreased PO2 could be used to alert clinicians to better monitor for signs of worsening and to provide more care in an attempt to reduce the growing mortality rate.

5. Conclusion

This study highlights the importance of sex variables in the measured laboratory test results, thus revealing the veil of the central role of the sex differences in the pathophysiology of the disease, which helps clinicians tailor treatments more effectively and improve patient care. This study also found that older age, male sex, higher serum total bilirubin level, and lower PO2 were independently predictive of mortality, which helps guide risk stratification for patients with diabetes and COVID-19.

Conflict of interest

None.

Research funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions

All authors have accepted responsibility for the entire content of this manuscript and approved its submission

References

[1] N. Zhu, D. Zhang, W. Wang, et al., A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (2020) 727–733.
[2] M.L. Holshue, C. DeBolt, S. Lindquist, et al., First case of 2019 novel coronavirus in the United States, N. Engl. J. Med. 382 (2020) 929–936.
[3] C.H. Mazurcani, J.M. Egan, SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? Immun. Ageing 17 (2020), 1–1.
[4] R.B. Kleotkota, E. Mirzala, W. Król, The etiology of lower respiratory tract infections in people with diabetes, Adv. Respir. Med. 83 (2015) 401–408.
[5] F. Feng, Q. Wang, H. Zhang, et al., The relationship between diabetes mellitus and COVID-19 prognosis: a retrospective cohort study in Wuhan, China, Am. J. Med. 134 (2020) e6–e14.
[6] D. Acharya, K. Lee, D.S. Lee, et al., Mortality rate and predictors of mortality in hospitalized COVID-19 patients with diabetes, Healthcare 8 (2020) 338–345.
[7] X. Yang, Y. Yu, J. Xu, et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir. Med. 8 (2020) 475–481.
[8] N. Chen, M. Zhou, X. Dong, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (2020) 507–513.
[9] F. Maasvais-Jarvis, Gender differences in glucose homeostasis and diabetes, Physiol. Behav. 187 (2018) 20–23.
[10] A. Kautzky-Willer, J. Harreiter, G. Pacini, Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus, Endocr. Rev. 37 (2016) 278–316.
[11] S. Ghosh, R.S. Klein, Sex drives dimorphic immune responses to viral infections, J. Immunol. 198 (2017) 1782–1790.
[12] C. Li, Q. Deng, J. Feng, et al., Clinical characteristics of diabetic patients with COVID-19, J. Diabetes Res. 2020 (2020) 1–5.
[13] Y. Meng, F. Wu, W. Lu, et al., Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients, PLoS Pathog. 16 (2020), e1008520.
[14] M. Grau, J.M. Cremer, S. Schmeichel, et al., Comparisons of blood parameters, red blood cell deformability and circulating nitric oxide between males and females considering hormonal contraception: a longitudinal gender study, Front. Physiol. 9 (2018) 1839–1846.
[15] B.B. Yeap, J. Beli, Z. Shi, et al., Serum testosterone levels correlate with haemoglobin in middle-aged and older men, Intern. Med. J. 39 (2009) 532–538.
[16] I. Quinti, V. Lougaris, C. Milito, et al., A possible role for β cells in COVID-19? Lesson from patients with agammaglobulinemia, J. Allergy Clin. Immunol. 146 (2020) 211–213.
[17] N. Gadi, S.C. Wu, A.P. Spilhal, V.R. Moulton, What’s sex to do with COVID-19? Gender-based differences in the host immune response to coronavirus, Front. Immunol. 11 (2020) 2147–2168.
[18] I. Santimone, A. Di Castelnuovo, A. De Curtis, et al., White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLO-SANI project, Haematologica 96 (2011) 1180–1188.
[19] M. Panova-Noeva, A. Schulz, M.J. Herrmann, et al., Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study, Blood 127 (2016) 251–259.
[20] Q. Zhong, J. Peng, Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19, J. Clin. Lab. Anal. (2020), e23607.
[21] E. Gúcchi, H. Kocayiğdı, H. Ökan, et al., Effect of COVID-19 on platelet count and its indices, Rev. Assoc. Med. Bras. 66 (2020) 1122–1127.
[22] B. Vozarova, N. Stefan, R.S. Lindsay, et al., High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes, Diabetes 51 (2002) 1889–1895.
[23] M.M. Phipps, L.H. Barraza, E.D. LaSota, et al., Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort, Hepatology 72 (2020) 807–816.
[24] R. Tian, M. Tian, L. Wang, et al., C-reactive protein for predicting cardiovascular and all-cause mortality in type 2 diabetic patients: a meta-analysis, Cytokine 117 (2019) 59–64.
[25] F. Liu, L. Li, M. Xu, et al., Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19, J. Clin. Virol. 127 (2020), 104370.
[26] R. Qu, Y. Ling, Y.H. Zhang, et al., Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19, J. Med. Virol. 92 (2020) 1533–1541.
[27] I. Karakoyun, A. Colak, M. Turken, et al., Diagnostic utility of C-reactive protein to albumin ratio as an early warning signal in hospitalized severe COVID-19 patients, Int. Immunopharmacol. 91 (2021), 107256.
[28] B. Hudzik, J. Szkodzińska, A. Lekston, et al., Mean platelet volume-lymphocyte ratio: a novel marker of poor short- and long-term prognosis in patients with diabetes mellitus and acute myocardial infarction, J. Diabetes Complications 30 (2016) 1097–1102.
[29] A. Kurutl, S.K. Akcigoz, Usefulness of mean platelet volume-lymphocyte ratio for predicting angiographic no-reflow and short-term prognosis after primary
percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction, Am. J. Cardiol. 120 (2017) 534–541.

[30] B. Hudzik, J. Szkodzinski, A. Lekston, et al., Mean platelet volume-to-lymphocyte ratio: a novel marker of poor short-and long-term prognosis in patients with diabetes mellitus and acute myocardial infarction, J. Diabetes Complications 30 (2016) 1097–1102.

[31] M.Z. Kocak, G. Aktas, E. Erkus, et al., Mean platelet volume to lymphocyte ratio as a novel marker for diabetic nephropathy, J. Coll. Physicians Surg. Pak. 28 (2018) 844–847.

[32] M.B. Pepys, C.M. Hirschfield, C-reactive protein: a critical update, J. Clin. Invest. 111 (2003) 1805–1812.

[33] E. Fairclough, E. Cairns, J. Hamilton, et al., Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome, Clin. Med. 9 (2009) 30–33.

[34] J.E. Park, K.S. Chung, J.H. Song, et al., The C-reactive protein/albumin ratio as a predictor of mortality in critically ill patients, J. Clin. Med. 7 (2018) 333.

[35] O.T. Rancani, F.G. Zampieri, D.N. Forte, et al., C-reactive protein/albumin ratio predicts 90-day mortality of septic patients, PLoS One 8 (2013), e59321.

[36] H. Duman, G. Cinier, E.M. Bakirci, et al., Relationship between C-reactive protein to albumin ratio and thrombus burden in patients with acute coronary syndrome, Clin. Appl. Thromb. Hemost. 25 (2019) 1–6.

[37] J.D. McFadyen, H. Stevens, K. Peter, The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications, Circ. Res. 127 (2020) 571–587.

[38] O. Mansour, S.H. Golden, H.C. Yeh, Disparities in mortality among adults with and without diabetes by sex and race, J. Diabetes Complications 34 (2020), 107496.

[39] F. Zhou, T. Yu, R. Du, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet 395 (2020) 1054–1062.

[40] A. Shenoy, M. Ismaily, M. Bajaj, Diabetes and covid-19: a global health challenge, BMJ Open Diabetes Res. Care 8 (2020), e001450.

[41] N.D. Yanez, N.S. Weiss, J.A. Romand, M.M. Treggiari, COVID-19 mortality risk for older men and women, BMC Public Health 20 (2020) 1–7.

[42] O. Tang, K. Matsushita, J. Coresh, et al., Mortality implications of prediabetes and diabetes in older adults, Diabetes Care 43 (2020) 382–388.

[43] S. Agarwal, C. Schechter, W. Southern, et al., Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019, Diabetes Care 43 (2020) 2339–2344.

[44] P. Palogiannis, A. Zinelli, Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis, Liver Int. 40 (2020) 1787–1788.

[45] Z. Liu, J. Li, W. Long, et al., Bilirubin levels as potential indicators of disease severity in coronavirus disease patients: a retrospective cohort study, Front. Med. 7 (2020), 558870.

[46] J. Xie, N. Covassin, Z. Fan, et al., Association between hypoxemia and mortality in patients with COVID-19, Mayo Clin. Proc. 95 (2020) 1138–1147.